The Global Drug sales of Dupixent stood at USD 11,587.52 Millions in 2023
The indicator recorded a historical growth (CAGR) of42% between 2020 to 2023 and is expected to grow by ...
GlobalData projects the indicator to grow at a CAGR of...
Dupilumab (Dupixent) is a monoclonal antibody developed based on VelocImmune technology. It is formulated as an injectable solution and injectable powder for solution for subcutaneous route of administration.
Mechanism of Action
Dupilumab (Dupixent) is a fully human monoclonal antibody that is designed to bind to IL-4RA. IL-4 increases the expression of eotaxin and other inflammatory cytokines from fibroblasts that might contribute to inflammation and lung remodelling in chronic asthma. Dupilumab targets IL-4 receptor alpha, involved in both IL-4 and IL-13 mediated effects, which play a central role in chronic allergic inflammation.
Dupixent Overview
Dupixent is indicated for the treatment of moderate to severe atopic dermatitis (eczema) in adults, in adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable, for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroid (ICS) plus another medicinal product for maintenance treatment, and to treat adults with nasal polyps (growths on the inner lining of the sinuses) accompanied by chronic rhinosinusitis (prolonged inflammation of the sinuses and nasal cavity) and as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. Dupixent is indicated for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Dupixent was first approved in 2017 and is sold globally including the US, the UK, France, Germany, and Japan by Sanofi and its subsidiaries. Dupixent drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
United States of America
United States of America
United States of America
United States of America
United States of America
United Kingdom
Switzerland
France
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer